TransMedics Group, Inc.
TMDXNASDAQHealthcareMedical Devices
As of Oct 16, 2026 close
- Market cap
- $3.12B
- P/E (TTM)
- 20.53
- Forward P/E
- 10.00
- Dividend yield
- -
- 52-week range
- $60.11$156.00
- Volume (live)
- -
- Avg. volume (3M)
- 791.99K
TransMedics Group (TMDX) Stock Price & Financial Analysis
TransMedics Group Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $70.03 - $76.52 |
|---|---|
| 52-Week High | $156.00 |
| 52-Week Low | $60.11 |
| Open | $76.52 |
| Volume (last close) | 1.07M |
| Average Volume (3M) | 791.99K |
| Revenue (TTM) | 668.47M |
|---|---|
| Net Income (TTM) | 151.70M |
| Free Cash Flow (TTM) | 79.04M |
| EPS (TTM) | $3.83 |
| Profit Margin | 22.69% |
| Operating Margin | 12.21% |
| Return on Equity (ROE) | 29.28% |
| Debt to Equity | 0.99 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 3.12B |
|---|---|
| Shares Outstanding | 40.71M |
| P/E Ratio (TTM) | 20.53 |
| Forward P/E | 10.00 |
| Price to Sales (P/S) | 4.66 |
| Price to Book (P/B) | 6.01 |
| EV/EBITDA | 26.31 |
| 50-Day MA | $85.62 |
|---|---|
| 200-Day MA | $98.13 |
| 1-Year Change | −34.95% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
TransMedics Group at a Glance
As of the Oct 16, 2026 close, TransMedics Group (TMDX) has a market capitalization of $3.12B. The stock trades at 20.5× trailing earnings, 10.0× forward earnings and 4.7× sales. Over the trailing twelve months it earned $151.70M on revenue of $668.47M (a 22.7% profit margin) and generated $79.04M of free cash flow. Revenue grew 25.8% year over year.
As of its latest reported balance sheet, it holds $472.68M in cash and securities against $514.00M of debt, a net debt position of $41.33M.
TransMedics Group does not currently pay a dividend.
The share price is down 34.9% over the past year. At $70.78 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $60.10 to $156.00, below its 200-day moving average of $98.13.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $97.44, 37.7% above the Oct 16, 2026 close.
Frequently Asked Questions About TransMedics Group
What is the current stock price for TMDX?
As of the Oct 16, 2026 close, TMDX stock trades at $70.78. The 52-week range is $60.11–$156.00, with a day range of $70.03–$76.52.
What is the P/E ratio for TMDX?
As of the Oct 16, 2026 close, TransMedics Group's trailing twelve-month (TTM) P/E ratio is 20.5, meaning investors pay $20.5 for every $1 of annual earnings. The forward P/E is 10.0, reflecting analyst expectations for future earnings. TransMedics Group operates in the Healthcare sector.
Does TMDX pay dividends?
TransMedics Group does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for TMDX?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for TMDX is Buy. The average 12-month price target is $97.44, a 37.7% upside from the Oct 16, 2026 close of $70.78.
What is the market cap of TMDX?
As of the Oct 16, 2026 close, TransMedics Group's market capitalization is $2.88B, classifying it as a mid-cap company. TransMedics Group operates in the Healthcare sector within the Medical Devices industry.